Personalized Multimodal and Opioid-Sparing Analgesia for Postoperative Pain Management: Enhancing Recovery and Addressing the Post-Discharge Gap

Introduction

Postoperative pain is among the most prevalent and poorly resolved problems in modern surgical medicine. With over 280 million procedures performed globally each year,¹ the incidence of moderate-to-severe postoperative pain ranges from 30% to 80% depending on procedure type and pain definition,² and persists after hospital discharge in 31% to 58% of patients.³ The failure to achieve adequate analgesia carries consequences that extend far beyond subjective discomfort—driving thromboembolic events, respiratory compromise, impaired wound healing, and psychological sequelae that collectively prolong hospitalization and worsen recovery.^4,5 Understood within a biopsychosocial framework,^6,7 postoperative pain is not a discrete physiologic signal but a multidimensional experience, and its management demands an equally multidimensional response.

Opioids, long the default analgesic cornerstone, have proven insufficient to that task. Beyond well-established risks of dependence and opioid-induced hyperalgesia,⁸ up to 80% of postoperative patients experience opioid-attributable cognitive impairment, fall risk, or rehabilitative delay,⁹ while NSAIDs—though adjunctively useful—carry prohibitive risk profiles in elderly and comorbid populations.¹⁰ These limitations have appropriately accelerated the shift toward multimodal, opioid-sparing strategies.¹¹

Yet the promise of multimodal analgesia^10–13 has outpaced its evidence base. Of 84 conceivable pharmacologic combinations, only acetaminophen plus NSAIDs is formally recommended¹⁴—and even this pairing is not without fault: preemptive acetaminophen failed to reduce opioid consumption in total knee arthroplasty,¹⁵ and intravenous formulations add little over oral equivalents.¹⁶ Optimal agent selection, dosing, and sequencing remain undefined,¹⁷ compounded by subjective pain assessment, variable clinical practice, and inadequate structured training in modern analgesic techniques.¹⁸ In cardiac surgery specifically, multimodal regimens remain so poorly characterized that nearly 30% of patients report persistent pain at one year.¹⁹

Regional techniques, particularly peripheral nerve blocks, offer meaningful short-term opioid sparing but are constrained by rebound phenomena, technical demands, and local anesthetic systemic toxicity risk.^20–25 More fundamentally, they do not reliably interrupt the progression to chronic postsurgical pain (CPSP)—a transition that is far more common than clinical practice acknowledges. Post-thoracotomy CPSP persists in 57% of patients at three months and 47% at six months;²⁶ after lung resection and knee arthroplasty, prevalence reaches 10% and 28% respectively at three months.²⁷ Neuropathic features, preoperative pain, anxiety, and depression independently predict this transition,²⁸ underscoring that acute and chronic pain exist on a continuum requiring prospective, risk-stratified intervention—not reactive treatment. The economic stakes are proportionate: in 2021, chronic pain affected an estimated 65.8 million U.S. adults, imposing a total societal burden of $722.8 billion in medical costs and lost productivity;²⁹ earlier estimates place annual costs at $560–$635 billion in 2010 dollars,³⁰ surpassing the combined burden of heart disease, cancer, and diabetes, with direct neuropathic pain syndromes alone generating nearly $42,000 per patient in annualized expenses.³¹ These gaps expose the absence of an integrative synthesis that evaluates the full spectrum of pharmacologic, regional, and non-pharmacologic analgesic strategies across their mechanisms, safety limitations, and clinical interactions — with attention to long-term outcomes including chronic postsurgical pain and opioid dependence. Accordingly, this review evaluates each analgesic modality and its role within multimodal frameworks, identifies procedure-specific evidence and critical gaps, and proposes evidence-informed, opioid-sparing analgesic principles aimed at supporting durable recovery across diverse surgical populations.

Epidemiology of Opioid Use and Opioid-Related Harm in the Perioperative Context

The liberalization of opioid prescribing for noncancer pain in the 1990s marked a pivotal inflection point in the contemporary opioid crisis. Converging forces—including relaxed state prescribing regulations, the introduction of pain management standards by accrediting bodies such as The Joint Commission, the designation of pain as the “fifth vital sign,” and aggressive pharmaceutical marketing—normalized long-term opioid therapy and expanded prescribing across clinical settings.^32–34 These shifts coincided with a near fourfold increase in U.S. sales of oxycodone hydrochloride and methadone hydrochloride between 1997 and 2002, during which accidental drug overdose emerged as the second leading cause of unintentional death.³⁵ Despite representing only 5% of the global population, the United States consumed 99% of hydrocodone bitartrate and 83% of oxycodone worldwide.³⁴ By 2010, opioid distribution reached 710 mg morphine sulfate equivalents per capita—sufficient to supply every adult with 5 mg of hydrocodone every six hours for 45 days—underscoring the extraordinary scale of opioid availability preceding the escalation of fatal overdose and heroin use across both urban and rural communities.^34,35

More than two decades later, opioid-related harm remains profound. In 2023, approximately 105,000 overdose deaths occurred in the United States, nearly 80,000 (76%) involving opioids.³⁶ Although opioid-related mortality declined modestly (4%) compared with 2022, deaths remain nearly tenfold higher than in 1999.³⁶ Trends varied by opioid class, with reductions in deaths attributed to prescription opioids, heroin, and synthetic opioids other than methadone, including illicitly manufactured fentanyl.³⁶

However, these aggregate improvements obscure a critical epidemiologic shift: in some jurisdictions, nearly half of overdose deaths involved concurrent opioid and stimulant use, highlighting the growing complexity of polysubstance exposure that challenges traditional opioid-centric interventions.³⁷

Opioid-related mortality also demonstrates marked heterogeneity across settings and populations. In Illinois, analysis of 2,833 opioid overdose deaths between 2017 and 2018 revealed that most fatalities occurred outside healthcare facilities, predominantly in private residences.³⁸ Hospital-based deaths were associated with prior overdose and bystander presence, emphasizing the importance of access to treatment, decriminalization strategies, and supervised consumption environments.³⁸ Importantly, declining opioid prescribing alone has not translated into proportional reductions in mortality. Between 2010 and 2015, U.S. opioid prescribing fell substantially, yet overdose deaths increased by 63%.³⁹ Among opioid-related decedents in Illinois, nearly one-third had not filled an opioid prescription in the preceding six years and were disproportionately Black, Hispanic, and urban residents.³⁹ These individuals were more likely to die from heroin or fentanyl analogues and less likely to have diagnosed opioid use disorder or access to buprenorphine treatment, underscoring structural inequities and the limits of prescription-focused mitigation strategies.³⁹ Within this broader epidemiologic landscape, surgical care represents a critical and underappreciated gateway to opioid exposure. Opioid use following surgery is associated with persistent use, opioid use disorder, and other serious adverse outcomes, yet postoperative opioid trajectories vary widely by procedure and patient characteristics.⁴⁰ For example, patients undergoing cervical laminectomy with fusion demonstrated higher six-month opioid use than those receiving laminoplasty in a single-surgeon cohort, although this association was not replicated in national datasets, highlighting the influence of contextual and provider-level factors.⁴¹

In orthopedic populations, preoperative opioid exposure and advanced joint pathology—but not surgical technique—were the primary predictors of prolonged postoperative use.^42,43 Conversely, in colorectal surgery, individualized multimodal care bundles incorporating tailored opioid regimens, scheduled gabapentinoids, and clonidine rescue reduced postoperative opioid consumption by more than two-thirds, demonstrating the modifiability of postoperative exposure when care is personalized.⁴⁴ Nevertheless, high-risk procedures such as cervical discectomy and fusion continue to be associated with substantial postoperative opioid prescribing and prolonged use (Figure 1), reinforcing the need for procedure-specific and patient-specific risk mitigation strategies.⁴⁵

Figure 1 This figure illustrates perioperative opioid exposure from initial surgical prescribing through the transition to outpatient care, highlighting a critical post-discharge gap where overprescribing, reduced monitoring, and inconsistent multimodal analgesia contribute to persistent opioid use and community harm. Evidence-based perioperative and discharge strategies can mitigate risk and reduce long-term opioid exposure. Inpatient flow Gap drives risk Community cascade Adverse escalation Indirect pathway. In patient Management gap Outpatient issues and risk Adverse outcomes Evidancy based solutions. Note: The central box connects to all outpatient boxes – Solid lines = direct drives, dashed= indirect escalation pathway.

A persistent and consequential gap emerges at the point of hospital discharge. Across multiple surgical cohorts, opioid prescriptions substantially exceed actual patient consumption. In elective surgery populations, surgeons prescribed nearly twice the amount of opioids consumed, leaving large quantities of unused medication vulnerable to diversion.⁴⁰ Similar patterns were observed across outpatient procedures, where fewer than one-third of prescribed opioids were used, and prescription size—not pain severity—was the strongest predictor of consumption.⁴⁶ Large-scale analyses demonstrate that more than half of postoperative opioid prescriptions exceed guideline recommendations, driven predominantly by prescriber-level factors rather than patient need.⁴⁷ Notably, evidence suggests that indiscriminate intraoperative opioid minimization may paradoxically worsen postoperative pain and increase persistent opioid use, underscoring the need for balance rather than elimination (Figure 1).^48–50

International and post-discharge data further expose critical deficiencies in perioperative opioid stewardship. In a multinational cohort spanning 25 countries, fewer than one-third of patients were prescribed opioids at discharge; however, when opioids were prescribed, quantities exceeded consumption by more than twofold.⁵¹ Regional variation was striking: while more than three-quarters of surgical patients in the United States and Canada received opioids within one week of discharge, only 11% did so in Sweden, highlighting the absence of globally harmonized, evidence-based discharge practices.⁵² Even within high-performing institutions, most patients consumed less than one-third of their prescribed opioids, few received disposal instructions, and a measurable proportion of opioid-naïve patients developed persistent use months after surgery.^53,54 Persistent post-surgical pain affects 10–35% of patients, highlighting critical gaps between clinical practice and patient outcomes.⁵⁵ Scoping reviews confirm that post-discharge pain is often inadequately managed despite effective inpatient multimodal analgesia, revealing a critical discontinuity between hospital-based care and outpatient pain management (Figure 1).⁵⁶ Notably, persistent postoperative opioid use occurs in up to 4.7% of opioid-naive adolescents.⁵⁷ Post-discharge analgesia often relies on clinician experience over guidelines, leaving patients with unmet expectations, inconsistent opioid use, and anxiety.⁵⁸

Enhanced Recovery After Surgery (ERAS) pathways have successfully reduced inpatient opioid use, length of stay, and early postoperative complications, particularly in orthopedic procedures.⁵⁹ However, reductions in in-hospital opioid exposure do not consistently translate into optimized discharge prescribing (Figure 1). In procedure-specific contexts such as cesarean delivery, ERAS implementation reduced the proportion of patients receiving opioids at discharge, yet most patients still received opioid prescriptions, often at high daily morphine equivalent doses.⁶⁰ These findings expose a persistent knowledge gap regarding post-discharge opioid exposure, long-term functional outcomes, and the optimal extension of multimodal analgesia beyond hospitalization.

Collectively, these data delineate critical unresolved epidemiologic gaps in perioperative opioid use. Existing research remains disproportionately centered on inpatient prescribing, despite mounting evidence that the greatest volume of opioid exposure occurs after hospital discharge.

Standardized, procedure-specific guidance for discharge prescribing is largely absent, contributing to wide inter-provider and inter-institutional variability. Moreover, patient-level risk factors—including prior opioid exposure, pain phenotypes, comorbid substance use, and sociodemographic determinants—are inconsistently incorporated into prescribing decisions. Finally, the disconnect between effective inpatient multimodal analgesia and largely unstructured outpatient pain management underscores a fundamental breakdown in continuity of care. Failure to address these gaps perpetuates avoidable opioid exposure without demonstrable improvement in postoperative pain outcomes, highlighting an urgent need for data-driven, perioperative-to-post-discharge analgesic frameworks.

Precision-Based Opioid Stewardship in Perioperative Pain

Opioid analgesics vary substantially in their pharmacological properties, clinical utility, and safety profiles, with important implications for postoperative pain management and public health. Despite significant advances in analgesic strategies, postoperative pain (POP) remains frequently undertreated, contributing to delayed recovery, prolonged hospitalization, and progression to chronic postsurgical pain.⁶¹ Contemporary perioperative pain management therefore requires not only effective analgesia but also careful consideration of opioid pharmacology, misuse risk, and interindividual variability in treatment response.

Tramadol provides analgesia through weak μ-opioid receptor agonism combined with inhibition of serotonin and norepinephrine reuptake. It is primarily metabolized hepatically via CYP2D6, with partial renal excretion of active metabolites.⁶² Epidemiologic data indicate that tramadol has a comparatively lower misuse potential than other commonly prescribed opioids. Between 2015 and 2017, tramadol accounted for approximately 4% of past-year opioid misuse, substantially lower than the 7–8% observed for hydrocodone or oxycodone after adjustment for drug availability.⁶³ Long-term analyses from 2002 to 2014 further demonstrate a stable misuse rate of approximately 1.5%, markedly lower than hydrocodone (6%), oxycodone (4%), and alprazolam.⁶³ Despite this favorable misuse profile, tramadol poses clinically significant risks, including serotonin syndrome, particularly in overdose, in CYP2D6 poor metabolizers with elevated parent-drug concentrations, or when co-administered with serotonergic agents such as selective serotonin reuptake inhibitors, serotonin–norepinephrine reuptake inhibitors, or tricyclic antidepressants, which may potentiate serotonergic toxicity and inhibit tramadol metabolism.⁶²

Prescribing patterns for fentanyl have undergone notable shifts. Population-adjusted outpatient use declined by 17.9% between 2016 and 2017, exceeding reductions observed for other prescription opioids, with pronounced decreases in states implementing stringent opioid regulations.⁶⁴ Nevertheless, substantial inter-state variability persists, with a reported 3.5-fold difference between Alaska and Oregon.⁶⁴ In contrast, hospital-based administration of fentanyl analogs, including remifentanil and sufentanil, tripled between 2006 and 2017, raising concerns regarding substitution effects and the downstream risks of misuse and diversion.⁶⁴ Clinically, fentanyl produces potent μ-opioid–mediated effects including analgesia, sedation, euphoria, respiratory depression, nausea, and urinary retention.⁶⁵ Misuse or dosing errors may precipitate severe adverse events such as chest wall rigidity, respiratory compromise, hypotension, cyanosis, and life-threatening arrhythmias (Figure 1).⁶⁶

Comparative perioperative research highlights important opioid-sparing opportunities. Intraoperative administration of dexmedetomidine has demonstrated superior postoperative outcomes compared with remifentanil, including reduced pain at 2 and 24 hours, lower postoperative opioid consumption, and fewer complications such as hypotension, shivering, and postoperative nausea and vomiting.⁶⁷ These findings support the need for individualized intraoperative opioid titration and careful selection of adjunct medications within multimodal analgesic strategies.

Tapentadol, a newer dual-mechanism analgesic, exerts synergistic analgesic effects through μ-opioid receptor agonism and norepinephrine reuptake inhibition, with enhanced noradrenergic signaling via α²-adrenergic pathways contributing to its efficacy.⁶⁸ Recommended dosing does not exceed 600 mg/day for immediate-release formulations.⁶⁹ Tapentadol provides effective analgesia for acute, chronic, and neuropathic pain and is associated with reduced nausea, constipation, and withdrawal severity, as well as lower μ-receptor affinity compared with traditional opioids.^69,70 Its modulation of noradrenergic neurotransmission shares functional similarities with certain antidepressant mechanisms, which may support improved tolerability and adherence in selected patient populations.⁶⁹

While informed opioid selection and stewardship are essential, substantial interindividual variability in analgesic response persists. This variability is increasingly attributed to genetic polymorphisms affecting opioid metabolism, transport, and receptor signaling—most notably CYP2D6, OPRM1, CYP2C9, COMT, and ABCB1—underscoring the clinical relevance of integrating pharmacogenomics into perioperative pain management.^61,71–73 Among these, CYP2D6 genotype exerts a particularly strong influence on opioid analgesic efficacy, especially for prodrug opioids such as codeine, tramadol, and hydrocodone.^74–77 Following knee arthroscopy, CYP2D6 poor metabolizers demonstrate significantly attenuated tramadol analgesia, whereas ultrarapid metabolizers experience the greatest pain reduction; in contrast, variants in ABCB1 (MDR1) show no significant effect in this setting.⁷⁴ Hybrid implementation–effectiveness trials further confirm the feasibility of CYP2D6-guided postoperative opioid prescribing after total joint arthroplasty, identifying approximately 20% of patients as high-risk metabolizers, increasing the use of alternative opioids, reducing overall opioid exposure, and achieving pain control comparable to usual care.⁷⁵

Beyond the perioperative setting, CYP2D6 polymorphisms also significantly influence opioid effectiveness in oncology populations, where intermediate and poor metabolizers experience inadequate analgesia, higher rates of pain-related hospitalizations, and more frequent escalation to opioids such as morphine or hydromorphone.^76,77 Collectively, these findings support consideration of preemptive CYP2D6 genotyping to inform opioid selection, enhance safety, and improve pain outcomes across both acute and chronic pain contexts.^71,78 The marked heterogeneity in opioid pharmacology, misuse potential, and genetically mediated response highlights the necessity of an integrated, precision-based approach to perioperative pain management. Combining evidence-based opioid stewardship with pharmacogenomic insights enables more individualized analgesic planning, optimizes patient safety, and represents a critical step toward sustainable, modern perioperative analgesia.

A pragmatic, scalable strategy to reduce perioperative opioid use is to systematically offer nonopioid analgesia as the foundation of postoperative pain management. Opioid monotherapy often provides suboptimal pain relief while increasing the risk of adverse drug events, dependence, and misuse. For many patients, scheduled nonopioid agents alone are sufficient, whereas others benefit from multimodal analgesic regimens, incorporating adjunct pharmacologic therapies and regional techniques. Collectively, these approaches reduce perioperative opioid exposure, enhance analgesic quality, and accelerate functional recovery.^79–82

The Table 1 summarizes contemporary perioperative multimodal analgesia strategies, aligned with recommendations from Enhanced Recovery After Surgery (ERAS), the American Society of Anesthesiologists (ASA), and PROSPECT guidelines.^83–85 While not exhaustive, it provides a practical framework for implementing opioid-sparing, evidence-based analgesia across diverse surgical populations.

Table 1 Clinical Protocol for Perioperative Multimodal Pharmacological Analgesics

Table 2 Pharmacologic Multimodal Regimens: Synergistic Effects and Clinical Limitations

Enhanced Recovery Analgesia

Opioids have traditionally been central to postoperative pain management but are associated with adverse effects—including nausea, vomiting, sedation, gastrointestinal dysmotility, respiratory depression, and immunosuppression—that can delay recovery. Enhanced Recovery After Surgery (ERAS) protocols therefore prioritize perioperative opioid minimization, reserving opioids for breakthrough pain when non-opioid strategies are insufficient. Opioid-tolerant patients represent an important exception, as scheduled opioid administration is required to prevent withdrawal. Although complete opioid avoidance is rarely feasible, ERAS pathways substantially reduce overall opioid exposure through as-needed dosing strategies (Table 1).

Multimodal analgesia, integrating pharmacologic and regional techniques targeting distinct nociceptive pathways, provides superior analgesia while enabling opioid dose reduction and limiting opioid-related adverse effects (Table 2).⁸⁶ These principles underpin ERAS protocols, which incorporate non-opioid medications and regional anesthesia to accelerate recovery through additive or synergistic effects.^7,87 In older adults, the American Geriatrics Society Beers Criteria identify potentially inappropriate medications; however, these are not absolute contraindications, and inappropriate substitution—such as replacing NSAIDs with opioids—should be avoided.⁸⁸

Adjunctive strategies—including regional anesthesia, acetaminophen, NSAIDs, gabapentinoids, tramadol, lidocaine, and NMDA antagonists—reduce perioperative opioid requirements without increasing bleeding risk, allowing many patients to avoid postoperative opioid therapy.⁸⁹ Evidence from systematic reviews and meta-analyses demonstrates that opioid-sparing multimodal analgesia reduces opioid consumption, pain scores, and ICU length of stay, including in large cardiac surgical populations, without adversely affecting mortality.⁷⁹ Accordingly, ERAS protocols endorse multimodal, opioid-sparing analgesia as a cornerstone of perioperative care.⁸⁴ Effective acute pain control accelerates recovery of function and quality of life, whereas inadequately treated pain may progress to chronic pain in up to 20% of patients.⁸⁴ Given persistently high opioid use and the complexity of managing opioid-dependent patients, international expert consensus and professional societies advocate individualized, multimodal analgesic strategies to reduce opioid-related complications and improve outcomes.^83,85

Observational and prospective studies across major surgical populations consistently demonstrate that incorporating regional anesthesia and comprehensive multimodal protocols improves postoperative pain control and reduces opioid requirements without increasing complications or length of stay.^90,91 Given the avoidable risks associated with opioid-based analgesia, ERAS pathways prioritize procedure-specific, predominantly non-opioid multimodal strategies, supported by growing evidence across diverse surgical disciplines.^80–82,92

Strategies for Opioid Reduction in Postoperative Pain Management

Post-operative pain impacts physical functioning, recovery, and quality of life, leading to anxiety. Effective management of pre- and postoperative pain is crucial in preventing chronic pain. Opioids are the main treatment for post-operative pain but come with unwanted side effects.²⁵ Nearly half of spine surgery patients already take opioids pre-operatively, raising addiction concerns.⁹³ A report published by the Academic Consortium in 2018 explored the reasons behind the widespread issue of pain management and offered scientific backing for using non-medication approaches to address pain.⁹⁴ Personalized pain plans are emerging to combat this, educating patients on pain management options, addressing potential opioid dependence, and prioritizing safer medications like NSAIDs/COX-2 inhibitors (with stomach considerations) or NMDA-receptor antagonists/antiepileptics (requiring monitoring) – all considering pre-operative and post-operative effects.^9,25,93

In the context of total knee arthroplasty (TKA), effective perioperative analgesia requires balancing pain control with safety. Preoperative administration of parecoxib sodium significantly lowered immediate postoperative pain (P = 0.039) without affecting surgical outcomes, complications, or analgesic consumption.⁹⁵ Preoperative meloxicam improved early pain management, reduced opioid consumption by ~40%, and maintained functional recovery at three months, highlighting its potential for enhancing perioperative opioid-sparing strategies.^96,97

Combination therapy with tramadol hydrochloride and acetaminophen (TRAM/APAP) outperformed NSAIDs alone, producing greater reductions in VAS pain scores and faster independent ambulation, emphasizing the value of synergistic multimodal analgesia.⁹⁸ While meloxicam offers gastrointestinal advantages over non-selective NSAIDs,⁹⁹ NSAID-associated risks—including transient renal impairment, platelet dysfunction, and increased cardiovascular events with long-term use—necessitate careful patient selection.^97,99,100 Variations in pharmacokinetics, including fat- versus water-soluble NSAIDs, may further influence toxicity profiles in elderly and obese populations.¹⁰¹ Prodrug formulations, such as acemetacin, may reduce gastrointestinal side effects, but robust comparative data are lacking.¹⁰² Despite clear evidence supporting the efficacy and opioid-sparing effects of these agents, gaps remain in understanding long-term functional outcomes, optimal dosing strategies (Table 2), and individualized risk mitigation. Tailoring analgesic regimens to patient-specific factors, including comorbidities, body composition, and pharmacokinetic profiles, is essential to maximize benefit and minimize harm.¹⁰² Additionally, the search for alternatives extends beyond medications, with ongoing research on Complementary and Alternative Medicine (CAM) for pain management.¹⁰³ Future studies should explore long-term safety, functional recovery, and comparative effectiveness across diverse populations to inform evidence-based multimodal perioperative pain management. Postoperative analgesia may include intravenous opioids and non-opioids—such as morphine, oxycodone, fentanyl, or bupivacaine—administered under the guidance of the surgeon and anesthetist, tailored to the patient’s pain needs after major surgery.¹⁰⁴

Adjuvant Therapies in Multimodal Analgesia

Adjuvant analgesics while individually beneficial are most effective when integrated into a broader multimodal framework (Table 2). Their use requires cautious titration from the lowest effective dose, particularly given the delayed onset of some agents, and an adequate therapeutic trial is essential before deeming a therapy ineffective.⁸⁷ Although certain adjuvants are employed for refractory pain syndromes such as back pain or temporomandibular disorders, it is important to acknowledge that evidence supporting these indications remains weak, highlighting a persistent gap in rigorous clinical data.⁸⁷

Analgesic effectiveness is shaped by fundamental pharmacologic features including onset, duration, and magnitude of relief that often parallel systemic drug exposure.¹⁰⁵ Yet despite advances in pharmacology, single-agent strategies continue to underperform in complex postoperative or geriatric pain states. This underscores the need to expand and standardize multimodal pain management approaches that integrate pharmacologic and non-pharmacologic modalities. Such comprehensive strategies have demonstrated the capacity to reduce opioid consumption, mitigate opioid-related complications, and enhance functional recovery in elderly hip-fracture patients, a population particularly vulnerable to adverse outcomes.^106,107

Non-pharmacologic interventions remain underutilized despite their established safety, accessibility, and minimal risk of harm. Techniques such as breathing exercises, massage, positioning, and music therapy form a broad spectrum of cognitive–behavioral, physical, and supportive approaches.^108,109 As outlined by Pölkki et al, these modalities not only complement pharmacologic therapy but empower patients, promoting self-efficacy and active engagement in pain control,¹⁰⁹ a critical component of enhanced recovery pathways Their low cost and favorable adverse-effect profile further support their routine incorporation into perioperative practice.^110–112

Current PROSPECT recommendations reflect the shift toward evidence-based multimodal regimens (Figure 2). For elective cesarean delivery under neuraxial anesthesia, intrathecal morphine (50–100 µg) or diamorphine (300 µg), combined with paracetamol/NSAIDs and IV dexamethasone, remains the cornerstone of optimized analgesia. When intrathecal opioids cannot be used, fascial plane blocks or wound infiltration provide effective alternatives, with TENS as an adjunct; opioids are relegated to rescue therapy.¹¹³ In Video-assisted Thoracoscopic Surgery, early continuation of non-opioid analgesics and the prioritization of regional techniques particularly paravertebral and erector spinae plane blocks reflect high-quality evidence favoring opioid-sparing strategies. IV dexmedetomidine is recommended when regional anesthesia is not feasible, further highlighting the move toward opioid minimization.¹¹⁴ Overall, synergistic multimodal analgesia protocols (MAPs) represent a critical evolution in perioperative care (Figure 2). By combining pharmacologic and non-pharmacologic strategies including regional anesthesia, acetaminophen, NSAIDs, ketamine, dexamethasone, and structured non-pharmacologic therapies MAPs consistently reduce pain severity, minimize opioid exposure, and improve postoperative recovery trajectories without increasing adverse effects (Table 2).¹¹⁵ Future research should focus on standardizing these multimodal pathways and identifying patient-specific predictors of response to further refine personalized analgesic care.

Figure 2 Schematic illustration of perioperative multimodal analgesia emphasizing the synergistic integration of complementary strategies to enhance analgesic efficacy, minimize treatment-related complications, and accelerate postoperative recovery, discharge, and rehabilitation. ↑: Increase, ↓: Decrease.

Systemic Non-Opioid Analgesic

Intravenous Acetaminophen

Intravenous paracetamol and propacetamol continue to show reproducible—but not uniformly transformative—analgesic effects across surgical and acute care settings.¹¹⁶ Meta-analytic evidence confirms that parenteral paracetamol achieves clinically meaningful pain relief (≥50% reduction) in only about one-third of postoperative patients, with a number needed to treat of 5,¹¹⁶ and ED data demonstrate modest opioid-sparing benefits.¹¹⁷ These findings underscore paracetamol’s value but also reveal its ceiling as a foundational rather than decisive component of multimodal analgesia. Safety considerations are increasingly central. Although acetaminophen is perceived as low risk, frailty-related pharmacokinetic alterations complicate this narrative. Frail older adults experience disproportionately elevated serum concentrations and reduced clearance, far exceeding changes attributable to chronological age alone.¹¹⁸ This decline—driven predominantly by impaired glucuronidation with preserved sulfation positions frailty,¹¹⁹ rather than age, as the critical determinant of hepatotoxicity risk, which may occur even at therapeutic doses.¹²⁰ Clinically, this reframes paracetamol as a drug requiring tailored dosing rather than routine administration in geriatric care.¹²¹ Hemodynamic instability following IV acetaminophen further challenges its routine use in high-acuity environments. Hypotension occurs in 10–60% of critically ill patients and demands intervention in up to 30%,¹²² raising concerns about unrecognized hemodynamic liability. Prospective observations reinforce this risk: over half of monitored adults experience substantial MAP reductions after infusion, with a median nadir of 64 mmHg and more than one-third requiring corrective measures.¹²³ Experimental evidence implicates N-acetyl-p-benzoquinone imine in a Kv7.4/7.5 channel–mediated vasodilatory cascade amplified by CGRP release, offering a mechanistic explanation and a potential target for mitigation.¹²⁴

Analgesic combinations containing paracetamol, such as paracetamol/codeine, can improve early postoperative pain control and reduce rescue analgesic needs relative to ibuprofen or placebo.¹²⁵ Yet large-scale instrumental-variable analyses challenge assumptions about its centrality to multimodal analgesia: NSAIDs combined with dexamethasone and regional anesthesia deliver the most clinically meaningful opioid-sparing effects, whereas acetaminophen’s contribution is comparatively modest and often overstated.¹⁷ These findings compel a recalibration of multimodal protocols that currently rely heavily on acetaminophen without strong evidence of incremental benefit. Ultimately, while dual-mechanism analgesia offers an advantage in early postoperative pain control with controlled opioid exposure, substantial uncertainties persist. Optimal dosing for frail geriatric patients remains undefined, hemodynamic safety in unstable or critically ill individuals is unresolved, and long-term recovery implications are largely unexplored.¹²⁶

Progress will require rigorously designed, stratified clinical trials incorporating validated frailty indices, mechanistically informed dosing frameworks, and real-time hemodynamic surveillance. Without such precision, acetaminophen’s role in personalized, opioid-sparing analgesic care will remain constrained by longstanding assumptions rather than robust evidence.

Dexmedetomidine

Growing evidence supports dexmedetomidine as a potent opioid-sparing adjunct with clinically meaningful benefits across perioperative settings. A meta-analysis demonstrated significantly reduced early postoperative pain compared with remifentanil (mean difference –0.7/10; 95% CI –1.2 to –0.2; P = 0.004) and improved 24-hour pain outcomes, reinforcing dexmedetomidine’s analgesic superiority with moderate-quality evidence.⁶⁷ Beyond analgesia, dexmedetomidine prolonged time to first analgesic request, lowered postoperative morphine and rescue analgesic use, and reduced hypotension, shivering, and PONV, while maintaining comparable bradycardia rates to remifentanil.⁶⁷ Standard dosing regimens (1 μg/kg bolus followed by 0.5 μg/kg/h infusion) attenuate perioperative hemodynamic stress and significantly reduce postoperative analgesic need during laparoscopic procedures.¹²⁷ Its capacity to lower anesthetic and opioid requirements, diminish postoperative nausea, vomiting, delirium, and agitation, and preserve respiratory drive positions dexmedetomidine as an attractive component of opioid-free anesthesia, especially for bariatric and spine surgery.¹²⁸

Mechanistically, dexmedetomidine’s analgesic, sedative, and possible antiemetic actions stem from targeted modulation of nociceptive transmission, suppression of sympathetic activation, and mitigation of hyperalgesia, with preclinical evidence supporting synergism with opioids.¹²⁹ These properties translate into improved postoperative comfort, reduced anxiety, shorter hospital stay, and enhanced recovery trajectories.¹³⁰ However, its expanding use must be balanced against concerns regarding hemodynamic instability. The increased risk of intraoperative bradycardia is well-documented, warranting careful patient selection and vigilant monitoring.¹²⁹ Evidence from thoracoscopic lung cancer surgery further suggests that dexmedetomidine not only reduces PONV and opioid use but also accelerates functional recovery, with data supporting an optimal dose of 0.4 μg/kg/h in this population.¹³¹ Despite these promising findings, questions remain regarding its safety in high-risk cardiovascular patients, dose-response relationships, and comparative effectiveness across surgical subgroups highlighting the need for rigorously stratified future trials.

Dexamethasone

Growing evidence supports perioperative dexamethasone as a valuable adjunct within multimodal analgesia for joint arthroplasty, yet its risk–benefit profile warrants more nuanced interpretation.

Consistent reductions in postoperative pain, opioid requirements, and length of stay following TKA and THA highlight its potential to enhance recovery pathways.^132–134 Notably, a single 8–10 mg intravenous dose appears sufficient for meaningful analgesic benefit, and additional dosing confers no clearly demonstrated advantage.^133,135 The enhanced recovery observed with delayed postoperative dosing and adjunctive warming techniques raises the possibility that dexamethasone’s immunomodulatory and metabolic effects may influence functional outcomes beyond simple analgesia.¹³⁶

However, emerging data identifying preoperative dexamethasone as an independent predictor of rebound pain (incidence 61.7%) signal an underrecognized paradox: while early analgesia improves, susceptibility to delayed hyperalgesic states may increase.¹³⁵ This phenomenon challenges assumptions about corticosteroid-mediated nociceptive modulation and underscores the need to contextualize analgesic benefits within a temporal framework. Furthermore, dexamethasone’s adverse-effect profile ranging from gastrointestinal irritation to neuropsychiatric symptoms remains clinically relevant, particularly in older or frail patients.¹³⁷ Current evidence supports dexamethasone as an effective perioperative adjunct, but important uncertainties persist regarding optimal timing, patient selection, and its interaction with rebound pain physiology. Future trials should incorporate mechanistic endpoints, stratify by vulnerability to hyperalgesia, and compare single versus staged dosing strategies to refine its integration into precision multimodal analgesia.

Ketamine

Ketamine has emerged as a potent multimodal analgesic with opioid-sparing properties, yet its role in perioperative pain management requires nuanced interpretation. Clinical trials demonstrate ketamine reduces postoperative pain intensity, morphine consumption, and delays rescue analgesia in cesarean sections under spinal anesthesia, indicating its value as a temporary but clinically relevant strategy.^121,138 Preoperative administration under general anesthesia appears optimal, particularly for high-pain surgeries including abdominal, thoracic, orthopedic, and spinal procedures.⁷⁰ Mechanistic insights suggest that ketamine’s analgesia extends beyond NMDA receptor blockade, potentially modulating emotional pain processing and influencing long-term pain perception.¹³⁹ Its antidepressant effects in refractory depression, PTSD, and substance use disorders underscore its dual utility in perioperative and chronic pain settings.¹⁴⁰ Low-dose IV infusions (<1.2 mg/kg/h) consistently demonstrate ~40% reductions in postoperative opioid consumption without major complications up to 48 hours, although optimal dosing regimens remain to be defined.¹⁴¹

Heterogeneity exists across populations. Pediatric studies reveal limited analgesic benefit over 72 hours, with sex differences affecting opioid use and sedation.¹⁴²

Combined methadone–ketamine regimens highlight the additive potential for opioid reduction post-lumbar arthrodesis, suggesting strategic synergies in multimodal protocols.¹⁴³ Systematic reviews and meta-analyses reinforce ketamine’s early analgesic efficacy and opioid-sparing impact, though sensitivity analyses indicate variability based on surgical type, dose, and timing.^144,145 Clinical trials in lumbar fusion support a S-ketamine:oxycodone ratio of 1:0.75 to achieve meaningful opioid reduction without increasing adverse events.¹⁴⁶

Despite robust analgesic effects, ketamine is not without limitations. Evidence for prolonged postoperative benefit is mixed, with variability in pediatric, minor, and major surgeries. Psychotomimetic effects, inflammatory modulation, and antidepressant outcomes offer additional mechanistic advantages, yet require careful risk–benefit consideration.^147–155 Emerging public health concerns, exemplified by “Tusi” misuse, highlight the need for regulatory awareness and research caution.¹⁵⁶ Intraoperative esketamine reduces pain, anxiety, depression, and neuroinflammatory markers, yet cognitive benefits remain unproven, reinforcing the need for targeted, individualized protocols.¹⁵⁵ Evidence in other surgical populations is mixed. A meta-analysis of 7RCTs (748 patients) found no significant reduction in postoperative pain after breast cancer surgery, although ketamine/esketamine reduced short-term postoperative depression and dizziness without affecting recovery quality.¹⁵⁷ In pediatric surgery, a meta-analysis of 23 randomized trials (1,996 children) showed that perioperative esketamine reduced emergence delirium, postoperative pain scores, adverse events, and PACU length of stay in tonsillectomy and adenoidectomy.¹⁵⁸ In elderly patients undergoing lumbar spine surgery, a randomized trial (n = 90) found that low-dose esketamine reduced perioperative opioid requirements, lowered early postoperative pain scores, attenuated inflammatory cytokine responses, and improved hemodynamic stability. Postoperative respiratory depression was reduced, with no increase in psychiatric adverse effects.¹⁵⁹ Ketamine exhibits robust analgesic and opioid-sparing effects, alongside potential mood and anti-inflammatory benefits. Nonetheless, variability in dosing, patient response, and adverse events underscores the need for cautious, evidence-driven use. Future research must clarify long-term outcomes and define optimal, multimodal analgesic strategies.

Magnesium

Intravenous magnesium exhibits clinically relevant opioid-sparing effects in perioperative analgesia, yet current evidence presents limitations that temper confidence in its widespread adoption. Synthesized data from 25 trials suggest reductions in 24-hour postoperative opioid consumption and improved analgesic profiles without major adverse events.¹⁶⁰ Beyond its NMDA-receptor–mediated analgesic action, magnesium may attenuate rebound hyperalgesia, as indicated by interscalene ropivacaine studies showing modest prolongation of block duration and enhanced 24-hour pain control.¹⁶¹ Meta-analytic evidence further supports its role in noncardiac surgery, reporting prolonged analgesic intervals and lower morphine requirements.¹⁶² However, substantial heterogeneity, variable dosing regimens, and inconsistent reporting of magnesium-related hemodynamic effects underscore the need for caution in interpretation.^163–165 Clinical use is further constrained in patients with atrioventricular conduction abnormalities, neuromuscular disorders, or renal impairment due to risks of toxicity, muscle weakness, and ECG disturbances, highlighting the importance of individualized patient assessment and monitoring.^164,166 Taken together, magnesium is a promising adjunct in multimodal analgesia, but its optimal dosing, patient selection, and true impact on postoperative outcomes require rigorous, high-quality trials with standardized protocols and safety monitoring to establish evidence-based recommendations.

Gabapentinoids

Gabapentinoids have attracted considerable attention as opioid-sparing adjuncts, particularly in spinal surgery, where consistent reductions in postoperative pain and opioid-related adverse events have been observed.¹⁶⁷ Pregabalin may offer incremental benefits over gabapentin, though conflicting reviews highlight substantial variability in effect size and clinical relevance.¹⁶⁸ Evidence supporting gabapentin’s role in reducing catheter-related bladder discomfort (CRBD) adds a potentially meaningful secondary indication.¹⁶⁹ Despite these advantages, accumulating safety data warrants a more conservative interpretation of their perioperative utility, especially in older, frail, or renally impaired populations. The dose-dependent interaction between gabapentinoids and opioids substantially increases the risk of oversedation and respiratory depression, particularly at preoperative doses exceeding 300 mg of gabapentin combined with >20 mg oxycodone.¹⁷⁰

Observational and mechanistic studies further indicate increased vulnerability during laparoscopic procedures, where respiratory compromise may be masked until emergence.¹⁷¹ Renal elimination necessitates strict dose reduction when creatinine clearance falls below 60 mL/min.¹⁷² While randomized trials indicate gabapentin does not increase long-term opioid use compared to placebo,¹⁷³ large observational datasets report heightened pulmonary risk, and small clinical trials suggest only modest analgesic benefit, highlighting a disconnect between efficacy and safety.¹⁷⁴ Gabapentinoids also contribute to dizziness, cognitive impairment, and respiratory complications, suggesting that routine administration may be unjustified. These findings advocate for a selective, patient-specific approach, with risk stratification based on age, renal function, surgical procedure, and perioperative opioid exposure.¹⁷⁵ Conversely, gabapentinoids emerge as a relatively effective non-opioid adjunct. Moving forward, rigorously designed trials are required to identify patient subgroups most likely to benefit, and systematically quantify respiratory and neurological risks to guide evidence-based, individualized perioperative analgesic strategies.

Lidocaine

Intravenous lidocaine represents a potent perioperative adjunct, yet its clinical adoption remains limited due to inconsistent protocols, uncertain patient selection, and variable reporting of systemic adverse effects.¹⁷⁶ Evidence on its efficacy compared to placebo across postoperative outcomes is marked by uncertainty, as highlighted in a Cochrane review emphasizing methodological limitations and heterogeneity.¹⁷⁷ Notably, lidocaine’s impact on pain scores beyond the initial 24-hour postoperative period appears minimal, and comparative evidence versus epidural anesthesia remains sparse, leaving its broader clinical utility unresolved.¹⁷⁷

Perioperative studies yield mixed results: for example, systemic lidocaine during video-assisted thoracoscopic surgery (VATS) under general anesthesia did not significantly reduce postoperative pain or enhance recovery,¹⁷⁸ whereas targeted local injections in thyroid surgery provided only modest improvements during early movement or coughing, with comparable overall analgesia.¹⁷⁹ Dosing precision is critical. Infusions should be calculated using ideal body weight, with a maintenance rate of 1–1.5 mg/kg/h (max 120 mg/h) for ≤24 hours, and a loading dose ≤1.5 mg/kg over 10 minutes. Contraindications include patients <40 kg and concurrent local anesthetic blocks.⁶ Properly administered, IV lidocaine can reduce chronic postsurgical pain, early postoperative pain, and opioid consumption, particularly following abdominal and breast surgery, though optimal dosing and long-term outcomes require further investigation.¹⁷⁶ Meta-analytic evidence demonstrates that perioperative IV lidocaine in abdominal surgery can reduce postoperative opioid use by up to 85%, accelerate gastrointestinal recovery (first flatus by 23 hours, first bowel movement by 28 hours), and shorten hospital stay by 1.1 days, without major adverse effects; however, its efficacy in other surgical populations remains uncertain.¹⁸⁰ Mechanistic studies indicate dose-dependent effects: high doses reduce central sensitization, while low doses attenuate peripheral hyperalgesia, with analgesic effects persisting hours post-infusion.¹⁸¹ These findings suggest lidocaine may modulate both peripheral and spinal sensitization in neuropathic and inflammatory pain models.

While perioperative IV lidocaine may accelerate bowel recovery, decrease opioid requirements, and mitigate inflammatory responses,¹⁸² its benefit must be interpreted cautiously. Pharmacokinetic studies indicate consistent plasma levels in patients up to 86 years old, with over 90% achieving therapeutic concentrations safely, suggesting age-based dose adjustments are generally unnecessary.¹⁸³ Nonetheless, heterogeneity in protocols, patient selection, and long-term outcome data necessitates further large-scale, stratified trials to clarify its efficacy, optimal dosing, and safety across diverse surgical populations.

Regional Analgesia Approaches

Regional analgesia within enhanced recovery pathways encompasses neuraxial and peripheral techniques that interrupt nociceptive transmission at distinct anatomical levels. Neuraxial approaches, including epidural analgesia and intrathecal opioids with or without adjuvants, provide dense central analgesia but require careful patient selection due to procedure- and comorbidity-specific risks. Peripheral strategies—such as paravertebral, transversus abdominis plane, brachial plexus, femoral, sciatic, and fascia iliaca blocks, as well as wound infiltration—offer targeted, opioid-sparing analgesia with reduced systemic drug exposure. These techniques may be delivered as single-injection or catheter-based interventions and can be implemented preoperatively to attenuate central sensitization or postoperatively to supplement multimodal regimens when early placement is not feasible.

Neuraxial Analgesia Within Opioid-Sparing Multimodal Strategies

Continuous epidural analgesia using local anesthetics combined with opioids, such as bupivacaine and morphine, provides meaningful improvements in postoperative pain control, particularly after major orthopedic procedures. However, within a multimodal analgesia framework, these benefits must be carefully balanced against procedure- and patient-specific risks.¹⁸⁴ Analgesic efficacy is most pronounced during the first 18–24 postoperative hours, yet supplemental systemic opioids are frequently required, underscoring the persistent challenge of achieving sustained analgesia while minimizing opioid exposure.^185,186 Traditional epidural techniques, although effective, are associated with higher complication rates in frail and cardiovascularly vulnerable patients, which has contributed to growing interest in ultrasound-guided peripheral nerve blocks as safer, opioid-sparing alternatives within multimodal strategies, despite their continued underutilization in clinical practice.⁹

Intrathecal morphine provides potent and prolonged analgesia and has been shown to significantly reduce postoperative opioid requirements, particularly following abdominal surgery. Nevertheless, its clinical utility is constrained by a narrow therapeutic window and an unpredictable dose–response relationship.¹⁸⁷ Increased rates of respiratory depression and pruritus, as well as delayed respiratory compromise reported in obstetric populations, highlight safety concerns that are relevant to other high-risk surgical patients and emphasize the need for careful dosing and vigilant postoperative monitoring.¹⁸⁸ In addition, systemic absorption of lipophilic opioids administered epidurally may contribute to gastrointestinal adverse effects, supporting consideration of local anesthetic–only neuraxial regimens in selected patients within a broader multimodal approach.¹⁸⁷ These findings indicate that while neuraxial opioids remain an important component of perioperative analgesia,¹⁸⁹ their use should be individualized according to surgical context, comorbid conditions, and overall risk profile.

Neuraxial analgesia, encompassing epidural and spinal techniques, contributes substantially to multimodal pain control through the use of opioids with distinct pharmacokinetic properties. Lipophilic opioids such as fentanyl and sufentanil provide rapid onset of analgesia with relatively short duration, whereas hydrophilic agents such as morphine and hydromorphone demonstrate slower onset but prolonged analgesic effects. Standard intrathecal morphine doses (0.1–0.5 mg) typically provide 6–24 hours of postoperative analgesia and reduce reliance on systemic opioids.¹⁹⁰ Common adverse effects include nausea, vomiting, pruritus, sedation, and respiratory depression.¹⁹¹ Although contemporary lower-dose strategies have reduced the incidence of respiratory complications, extended-release epidural morphine (10–30 mg) has been associated with a significantly increased risk of respiratory depression (OR 5.80; 95% CI 1.05–31.93), leading to recommendations from the ASA for at least 48 hours of postoperative monitoring, particularly in high-risk populations.^70,191

Postoperative opioid exposure remains associated with a broad range of adverse outcomes, including nausea, vomiting, urinary retention, sleep disturbance, respiratory depression, somnolence, dizziness, delayed recovery, and opioid-induced hyperalgesia.⁹³ Opioid-induced hyperalgesia, particularly associated with high-dose intraoperative opioids such as remifentanil, may paradoxically increase postoperative pain, lower pain thresholds, and contribute to the development of chronic postsurgical pain.^93,192 While the overall incidence of opioid misuse following surgery is relatively low (approximately 0.6%), duration of opioid therapy is a critical determinant of risk; each prescription refill is associated with a 44% increase in misuse likelihood, and each additional week of opioid use increases risk by nearly 20% (Figure 1).¹⁹³ These findings reinforce the importance of neuraxial techniques as part of opioid-sparing multimodal analgesic strategies, alongside careful patient selection, ongoing assessment of analgesic efficacy, and close monitoring for adverse effects to optimize both short- and long-term postoperative outcomes.

Regional and Fascial Plane Blocks in Postoperative Pain

Regional and fascial plane blocks (FPBs) have emerged as cornerstone strategies in multimodal postoperative analgesia, yet their clinical utility must be carefully interpreted in the context of patient outcomes, procedural complexity, and risk-benefit balance. Thoracic epidural analgesia (TEA) and paravertebral blocks (PVBs) continue to demonstrate superior pain control, accelerated extubation, and reduced rescue analgesia requirements in cardiac surgery.^194–196 However, the clinical adoption of TEA is limited by hemodynamic instability, risk of spinal hematoma, and potential neurologic injury, highlighting the importance of meticulous perioperative monitoring.¹⁹⁷ Ultrasound-guided fascial plane blocks, including serratus anterior plane (SAPB) and erector spinae plane (ESPB) blocks, present safer alternatives with reduced procedural risk, yet their analgesic potency does not consistently match TEA, indicating that opioid-sparing alone may not reflect true analgesic quality.^196,198 TAPB reduces perioperative opioid consumption and improves early pain scores in orthopedic and abdominal surgeries, demonstrating clear analgesic benefit in both periacetabular osteotomy and laparoscopic colorectal surgery.^199,200 Nonetheless, TAPB does not consistently affect hospital stay or long-term outcomes, and superior analgesic efficacy of subarachnoid morphine must be weighed against higher adverse events.¹⁸⁸

FNB and FICB are effective in elderly hip fracture patients, providing early analgesia and reducing opioid requirements.^201–203 Evidence confirms their safety in cognitively impaired populations, although quadriceps motor blockade may increase fall risk.^201,204 Comparative studies of US-guided FNB, blind FICB, and continuous FICB highlight similar analgesic outcomes, with continuous blocks offering extended opioid-sparing benefits but potentially delaying early rehabilitation.^205–207 These findings underscore the trade-offs between analgesic duration, functional recovery, and procedural complexity. Thoracic, cardiac, and breast surgery pain control benefit from fascial plane blocks such as SAPB, PECS II, DPIPB, and ESPB.^{195,208–215} These blocks reduce opioid requirements, improve early recovery, and maintain hemodynamic stability, supporting their role as opioid-sparing adjuvants. Notably, modified S-FICB and US-FICB optimize analgesia in hip arthroplasty and hip fracture, demonstrating effective blockade of multiple target nerves.^216,217 Meta-analytic evidence further corroborates FICB’s early postoperative pain reduction and decreased opioid use in total hip arthroplasty.²¹⁸

Despite overall efficacy, heterogeneity persists across studies. Some blocks show comparable outcomes in intermediate-term recovery, while continuous techniques may affect early mobility.²⁰⁷ Moreover, the risk of motor blockade, the need for ultrasound guidance, and procedural expertise highlight practical limitations.^{201,204–206} Emerging evidence suggests quadratus lumborum and lumbar ESP blocks outperform standard analgesia in hip and proximal femoral surgeries, underscoring the potential for optimized, procedure-specific regional strategies.²¹⁹ However, critical appraisal of FPBs also emphasizes safety and systemic considerations. LAST, though rare, poses a high-stakes complication, particularly in brachial plexus blocks, with seizures exacerbated by hypoxia, hypercapnia, and acidosis.^220,221 Additionally, rebound pain and motor impairment remain notable limitations, potentially delaying rehabilitation and increasing fall risk.^11,25 Nonetheless, when integrated thoughtfully within a multimodal framework, nerve blocks remain powerful adjuncts capable of improving recovery trajectories.¹¹ These findings underscore that advanced analgesic techniques deliver significant opioid-sparing effects, superior pain control, and faster recovery.^194,222 However, implementation requires balancing efficacy, safety, and functional outcomes.^189,223 Future research should prioritize comparative effectiveness, long-term outcomes, and integration into multimodal analgesic protocols across varied surgical populations.

Continuous Regional Analgesia Catheters

Continuous and single-shot regional analgesic strategies demonstrate variable efficacy and resource demands, underscored by evidence from multiple surgical settings. The transmuscular quadratus lumborum block (QLB) achieved lower pain scores at rest (p = 0.036) and higher patient acceptance (p = 0.004, p = 0.006) than pre-peritoneal catheter blocks, albeit at a substantial additional cost.²²⁴ In total hip arthroplasty, continuous femoral nerve block (FNB) provided superior analgesia during movement at 6 hours (median 38 vs 67, p = 0.008) and 24 hours (median 39 vs 60, p = 0.018) compared to continuous QLB, highlighting inconsistencies in sensory blockade and suggesting procedure-specific optimization is required.²²⁵

Continuous regional and neuraxial blocks remain potent tools for severe postoperative pain, yet high failure rates—particularly with epidural catheters—limit their universal application.²²⁶ Novel applications, such as the erector spinae plane block with continuous infusion, demonstrate feasibility in enabling safe postoperative physiotherapy, illustrating how ultrasound guidance may mitigate complications.²²⁷ Dual-catheter strategies targeting popliteal and saphenous nerves enhanced analgesia, increased patient satisfaction, and reduced opioid requirements, suggesting that selective, multi-targeted approaches may improve outcomes.²²⁸ Evidence regarding adductor canal blocks (ACB) indicates that single-shot techniques provide equivalent pain relief and functional recovery to continuous ACB within the first 48 hours after total knee arthroplasty, whereas continuous ACB increases complication risks without clear analgesic superiority.²²⁹ Similarly, continuous brachial plexus blocks extend analgesia but impose high logistical and safety burdens, including infection risk, device failure, and up to 5% catheter displacement within 6 hours.²³⁰ These findings highlight the tension between theoretical analgesic advantages and practical limitations, underscoring the importance of evidence-based implementation of continuous PNBs.

Safety Considerations in Regional and Neuraxial Analgesia

Although local and regional anesthetics are cornerstone modalities for perioperative analgesia, their safety profile is constrained by dose-dependent neurotoxicity and cardiotoxicity. High doses can induce neuronal hyperexcitability, manifesting as tremors or seizures, and impair cardiac conduction, reducing contractility.²³¹ Notably, bupivacaine, ropivacaine, and mepivacaine demonstrate preferential toxicity toward degenerated cartilage, with chondrocyte injury mediated via both necrotic and apoptotic mechanisms, a pattern not predicted by analgesic potency.²³² This underscores the need to consider tissue-specific toxicity when selecting local anesthetics, particularly in degenerative joint disease. Peripheral nerve blocks carry functional trade-offs. Continuous lumbar plexus and femoral nerve blocks effectively control postoperative pain but substantially increase fall risk due to transient quadriceps weakness.^233–235 Fascia iliaca compartment blocks similarly compromise muscle strength in the immediate postoperative period.^207,236 Interscalene blocks present additional safety concerns, with 34% of patients in one study developing postoperative respiratory difficulties.²³⁷ Neuraxial anesthesia, while broadly safe, has rare yet severe adverse outcomes. Data from Sweden highlight that two-thirds of serious events result in permanent injury, predominantly from epidural hematomas rather than infections.¹⁹⁷ Rebound pain following nerve blocks further complicates postoperative management.^25,238 Preexisting neurologic disease markedly increases susceptibility to neuraxial complications (0.3–1.1%), far exceeding general population rates (0.001–0.07%), with serious outcomes requiring decompression occurring in <0.05%. Peripheral nerve injuries are typically transient but remain a clinical concern.¹⁹⁷

Epidural analgesia balances efficacy with a spectrum of potential adverse effects. Local anesthetics can induce hypotension, sensory and motor deficits, and urinary retention, whereas epidural opioids add pruritus, nausea, vomiting, and respiratory depression. Technique-related risks, including post-dural puncture headache, catheter-related back pain, and epidural hematoma, emphasize the importance of procedural expertise. Concurrent anticoagulation—particularly with LMWH, unfractionated heparin, warfarin, or newer antiplatelet agents—increases hematoma risk, reinforcing the necessity for strict adherence to safety protocols.¹⁸⁷ These data highlight that while regional anesthesia provides powerful analgesic benefit, its implementation must be individualized, integrating patient comorbidities, anticoagulation status, and tissue-specific vulnerabilities to optimize safety and outcomes.

Non-Pharmacological Pain Management(NPM)

Non-pharmacological interventions are increasingly incorporated into multimodal postoperative analgesia, yet their clinical impact remains inconsistent. Physical modalities—including TENS, acupuncture, massage, and temperature therapies—show variable efficacy.²³⁹ Large-scale observational data from 14,767 European patients revealed that 44.4% utilized at least one NPM, reporting slightly lower pain relief (68.6% ± 25.7%) than non-users (71.2% ± 27.9%, p<0.001), indicating that NPM use does not universally translate into superior analgesia.²⁴⁰ Evidence from 69 RCTs demonstrates nuanced outcomes. Specific acupressure decreased pain by WMD −2.09 cm on a 10-cm VAS (moderate certainty), while supervised rehabilitation paradoxically increased pain (WMD +1.06 cm). TENS reduced pain modestly (WMD −1.18 cm, low certainty), and acupressure improved function (WMD +1.51 cm). Laser therapy strongly enhanced symptom relief (OR 32.08), whereas mobilization had limited benefit (OR 7.99). Treatment satisfaction effects were generally absent.²⁴¹ These findings underscore that while certain NPMs offer measurable benefits, the overall contribution to postoperative pain control is modest.^103,242,243

Preoperative anxiety affects 11–80% of surgical patients and significantly influences intraoperative anesthetic dosing and postoperative analgesic requirements.²⁴⁴ Anxiety and pain are shaped by both biological and psychosocial factors, leading to wide interindividual variability.²⁴⁵ Clinical studies show that higher preoperative anxiety and pain sensitivity predict greater postoperative pain and analgesic use.^246,247 Meta-analyses demonstrate that preoperative anxiety increases anesthetic (SMD 0.67) and analgesic needs (SMD 0.89), prolongs recovery and raises the risk of postoperative delirium (OR 1.90) in adults.²⁴⁸ These findings underscore the need for individualized anesthetic management and integrated perioperative psychological assessment.^249,250

Psychological strategies—including pre- and postoperative education, cognitive behavioral therapy(CBT),²³⁹ and distraction methods—may reduce reliance on analgesics. CBT effectively mitigates postoperative anxiety and depression, particularly in older women, but its influence on pain scores is less definitive.²⁵¹ Evidence for psychological preparation and acupuncture remains mixed.^239,252 Techniques such as guided imagery, relaxation, hypnosis, intraoperative suggestions, and music therapy show potential, yet implementation is constrained by institutional barriers, including nurse workload, time limitations, and insufficient training.^94,253 Overall, non-pharmacological strategies play a safe and valuable adjunctive role within multimodal analgesia, although heterogeneous interventions and patient populations limit generalizability and highlight the need for standardized protocols integrated with pharmacologic care. Evidence suggests that perioperative education, empathetic communication, and avoidance of nocebo language can improve pain control, reduce opioid use, and shorten hospital stay. Mindfulness and cognitive behavioral therapy support recovery, physical therapy enhances function, and modalities such as cryotherapy, acupuncture, and TENS provide modest, procedure-specific analgesic benefits.²⁵⁴ Despite growing evidence that psychological interventions and structured patient education can reduce perioperative pain and anxiety, their routine incorporation into anesthetic practice is variable, and their clinical impact is maximized when delivered alongside established pharmacological analgesic strategies rather than as standalone approaches.⁸⁷

Pharmacist Contributions to Perioperative Pain Management

Clinical pharmacists are increasingly recognized as essential members of perioperative care teams, improving the quality, safety, and effectiveness of multimodal analgesia. Multisite quality initiatives demonstrate that pharmacist-led perioperative pain management delivers individualized analgesic strategies, mitigates opioid-related risks, and achieves high adherence to guideline-recommended practices, with strong endorsement from orthopedic and surgical teams.^255–257

Integration of pharmacists into transitional perioperative care enhances continuity across surgical phases, enabling tailored analgesic planning and patient-centered interventions, which improve satisfaction among both patients and providers.²⁵⁶ Effective multimodal and opioid-sparing analgesia relies not only on evidence-based drug selection but also on reliable, patient-specific implementation; pharmacists facilitate this process by optimizing medication regimens, monitoring for adverse drug reactions, and supporting opioid stewardship within interdisciplinary teams.^255,256

Evidence demonstrates tangible clinical benefits. Pharmacist-led perioperative pharmaceutical care in orthopedic surgery reduced postoperative pain scores and shortened hospital stay by an average of 2.3 days, without compromising breakthrough pain control or safety.²⁵⁸ In ambulatory surgery, pharmacist consultations decreased moderate-to-severe postoperative pain by 17% and reduced mean pain scores by 0.9 points.²⁵⁹ Pharmacist interventions also reduce medication errors, enhance adherence to protocols, and improve overall perioperative safety through multicomponent strategies including medication reconciliation, staff education, and patient counseling.^260,261 Despite growing evidence, implementation remains inconsistent. Surveys indicate that while most pharmacists support involvement in postoperative pain management, actual engagement is limited due to a lack of standardized protocols, systematic training, and structured workflows.²⁶² Evidence gaps persist regarding chronic disease management, development processes for interventions, and the long-term impact of pharmacist integration on patient-centered outcomes.²⁶³ Collectively, these data highlight the transformative role of clinical pharmacists in perioperative care. Their integration supports individualized, multimodal analgesia, enhances interprofessional collaboration, reduces opioid exposure, and strengthens patient safety. Structured programs and professional education are essential to maximize pharmacists’ impact, standardize care delivery, and promote sustainable, high-quality perioperative pain management.²⁶⁴

Personalized and Precision Multimodal Approaches to Perioperative Pain Management

Personalized Multimodal Perioperative Pain Management

Postoperative pain remains a major clinical challenge despite advances in analgesic strategies. Retrospective studies show that preoperative opioid or benzodiazepine use, smoking, and obesity increase postoperative opioid requirements, while age and sex have minimal impact.²⁶⁵ Evidence for preemptive opioids is limited. A Cochrane review of 20 RCTs (1,343 participants) found modest reductions in postoperative pain but no clear benefit for preventive opioids (Figure 1). Adverse events were underreported, highlighting the need for high-quality trials.²⁶⁶ Guidelines from the American Pain Society recommend multimodal analgesia for all surgeries, targeting multiple pain pathways and accounting for interindividual variability, including pharmacogenetic differences in opioid metabolism and pain sensitivity (Figure 3).²⁶⁷ Prospective studies, such as a post-cesarean cohort in Uganda, reveal gaps in care: pain peaked six hours postoperatively (median 37/100), and 32% of patients reported inadequate analgesia despite standard regimens.²⁶⁸ Personalized multimodal strategies improve recovery by integrating biological, psychological, and social determinants of pain. Interventions such as dynamic monitoring, virtual reality therapies, and prehabilitation reduce pain scores, opioid use, and hospital stay. AI-supported decision tools and standardized protocols have the potential to enhance these outcomes further.²⁶⁹

Figure 3 This figure illustrates a precision-guided approach to perioperative pain management. Advanced technologies, including pharmacogenomics, artificial intelligence, and real-time patient monitoring, converge to support an opioid-sparing personalized analgesic optimization strategy. This strategy informs a multimodal analgesic plan incorporating tailored systemic analgesics and clinical pharmacist oversight for medication safety and opioid tapering, ultimately improving pain control, reducing opioid use, enhancing recovery, and shortening hospital stay. Feeds into Generates plan Produces outcome Lateral input. Input Pillars Personalized Multimodal Analgesic Plan & tracks Improved Patient Outcomes.

Minimally invasive procedures, including arthroscopic surgery, benefit from opioid-sparing multimodal approaches. NSAIDs, acetaminophen, gabapentinoids, and local anesthetics reduce opioid exposure while enhancing functional recovery. Randomized trials show nonopioid multimodal regimens lower pain scores (VAS, PROMIS-PI) and adverse effects compared with opioid-based therapy.^270,271 Limiting opioid exposure is critical, given the U.S. overdose crisis, with 94,000 deaths in 2020. Evidence-based prescribing, procedure-specific pill counts, and standardized care pathways are essential for safe postoperative management.²⁷² Provider knowledge impacts outcomes. In a study of 72 ICU nurses, only 21.6% applied behavioral pain scales for non-communicative patients, despite universal use of standard scales. Knowledge gaps correlated with gender, education, and prior pain training, highlighting the need for structured education and broader adoption of validated assessment tools.²⁷³ Perioperative pain management is evolving toward patient-centered, individualized care. Personalized strategies consider comorbidities, psychological status, and pain sensitivity to optimize recovery and reduce complications. Multimodal, individualized care can lower pain scores by 20–30%, opioid use by 25–40%, and hospital stay by 1–2 days.^269,274

Despite over 800 primary studies and 107 systematic reviews, critical gaps remain. Evidence is limited regarding optimal patient education, nonpharmacological interventions, analgesic combinations, monitoring of treatment response, neuraxial and regional techniques, and care delivery models.²⁷⁵ Quality metrics are also insufficient: of 19 identified measures, only five are endorsed by the National Quality Forum. None specifically targets postoperative pain, and only three non-endorsed measures address it, highlighting a lack of standardized benchmarks.^276,277

Pharmacogenomic-Guided Multimodal Analgesia

Pharmacogenomics addresses a critical gap in perioperative pain management by accounting for genetically mediated differences in pharmacokinetics, pharmacodynamics, and pain perception.^71,72 Adverse drug reactions—many of which are genetically influenced—remain a major source of preventable morbidity, mortality, and healthcare expenditure, with their true burden likely underestimated due to underreporting.⁶¹ Although pharmacy-related costs account for less than 5% of total surgical expenditure, inadequately controlled postoperative pain substantially increases overall costs through prolonged hospitalization, delayed functional recovery, and progression to chronic pain, supporting the economic rationale for targeted pharmacogenomic testing in selected patient populations.⁶¹

Randomized and observational studies increasingly demonstrate that pharmacogenetic-guided multimodal analgesia is associated with reductions in postoperative pain scores and opioid consumption, particularly among patients harboring actionable genetic variants.^278,279 When integrated with clinical risk stratification tools and guideline-endorsed multimodal analgesic strategies,^267,280,281 pharmacogenomic-informed care represents a scalable, evidence-based pathway toward precision perioperative pain management.

Patient-Controlled Analgesia Within Personalized Pain Pathways

Patient-controlled analgesia (PCA) remains a cornerstone of acute postoperative pain management, enabling individualized, on-demand opioid delivery for surgical, trauma-related, and chronic pain in both adults and children older than five years.²⁸² Its widespread use in perioperative care reflects its ability to reduce the analgesic “perception–delivery gap”; however, clinical outcomes are highly dependent on opioid selection, pump programming, and patient-specific factors.²⁸³ Hydromorphone and sufentanil are among the most commonly administered opioids for PCA, yet direct comparative evidence regarding their postoperative efficacy and safety remains limited, with available studies yielding inconsistent results.²⁸³ Opioid-induced pruritus—particularly frequent with morphine—often necessitates opioid rotation, with hydromorphone frequently favored because of its comparatively improved tolerability profile.²⁸⁴

Comparative studies demonstrate that hydromorphone- and sufentanil-based IV-PCA generally provide similar analgesic efficacy across diverse surgical contexts.^285,286 Notably, in colorectal cancer surgery, hydromorphone improved mood recovery at 48–96 hours yet increased pruritus and nausea relative to sufentanil,²⁸⁶ underscoring the nuanced balance between analgesic benefit and tolerability. Randomized evidence further suggests that fentanyl–ketamine IV-PCA may serve as a viable alternative to thoracic epidural analgesia after minimally invasive thoracic surgery; both techniques produced comparable analgesia and adverse effect profiles, though fk-IVPCA resulted in more early postoperative demands.²⁸⁷ These findings highlight the growing role of multimodal PCA strategies, particularly in settings where epidural analgesia is contraindicated or technically challenging. Despite its advantages, PCA is not without risk. Sufentanil, while potent, may induce respiratory depression and thereby jeopardize postoperative safety, particularly in high-risk surgical populations.²⁸⁸ Moreover, many PCA-related complications including programming errors, excessive dosing, and respiratory depression stem from human factors rather than the device itself,²⁸² highlighting the need for standardized training and monitoring.

Recent pediatric data illustrate the potential benefits of opioid-sparing PCA strategies: nalbuphine/dexmedetomidine PCIA supported superior hemodynamic stability, analgesia, sedation, and stress control compared with sufentanil/dexmedetomidine in tonsillectomy, with fewer adverse reactions.²⁸⁹ Age also modifies PCA pharmacodynamics: younger recipients of fentanyl PCA have higher rescue analgesic requirements—attenuated by ketorolac—whereas older adults benefit from prophylactic antiemetics such as ramosetron.²⁹⁰ Incorporating adjunct non-opioid analgesics (paracetamol, NSAIDs, local anesthetics, ketamine, tramadol) effectively reduces opioid consumption but demands caution in patients receiving concurrent sedatives or with renal/hepatic dysfunction due to metabolite accumulation (eg, morphine (M3G, M6G) and hydromorphone (H3G).²⁹¹

Common opioid-related side effects sedation, nausea, vomiting, and pruritus typically remain manageable with dosage adjustment or supportive medication,^292,293 though constipation and urinary retention warrant ongoing surveillance.²⁹³ Importantly, emerging evidence questions routine PCA use in certain low-to-moderate pain surgeries: in laparoscopic cholecystectomy, morphine PCA was associated with delayed recovery, impaired alertness, and significantly higher postoperative nausea and vomiting compared with non-PCA protocols.²⁹⁴ These findings suggest that reflexive postoperative PCA prescribing may be inappropriate in procedures with predictable, mild-to-moderate pain trajectories. Basal opioid infusion via IV-PCA was previously used to enhance postoperative pain control; however, it does not improve pain or sleep quality and increases opioid-related side effects.²⁹⁵ A meta-analysis of 796 patients showed basal IV-PCA significantly raises respiratory depression risk, leading to recommendations against its routine use.²⁹⁶ Despite this, basal fentanyl infusion in IV-PCA continues in practice.²⁹⁵ Most existing evidence comes from morphine-based IV-PCA studies with small sample sizes, highlighting the need for research on the risks and benefits specific to fentanyl’s distinct pharmacokinetics.²⁹⁵

PCA provides superior postoperative pain relief and patient satisfaction compared to traditional methods, allowing self-titration and immediate analgesia. Morphine is first-line; alternatives include hydromorphone and fentanyl. PCA should integrate non-opioid analgesics, with careful monitoring for sedation, respiratory status, and side effects.²⁹⁷ Special considerations apply for pediatric, elderly, and emergency surgery patients, emphasizing education and safety protocols.^297,298 Smart pump technology enhances safety by reducing errors, but proxy use, continuous infusions, or programming mistakes pose risks. Optimizing outcomes requires standardized protocols, staff training, and a multidisciplinary approach integrating technology, clinical oversight, and procedural rigor.²⁹⁸

Machine Learning in Postoperative Pain Management

Recent studies have applied machine learning (ML) to personalize perioperative and postoperative pain management, enabling individualized analgesic strategies that account for patient variability in pain response and opioid effectiveness. The OPIAID algorithm leverages observational electronic health record data and causal modeling to predict optimal opioid doses based on patient characteristics, intraoperative factors, and opioid type, aiming to maximize analgesia while minimizing opioid-related adverse events.²⁹⁹ The Interpretable Neural Network Regression (INNER) model combines deep neural networks with traditional statistical methods to assess preoperative opioid use risk. Applied to 34,186 surgical patients, INNER generated interpretable, patient-specific risk estimates, identified key predictive factors, and supported evidence-based individualized pain management.³⁰⁰

In obstetric populations, ML models such as XGBoost have been used to optimize post-cesarean pain management. Among multiple models tested, XGBoost performed best, highlighting critical predictors including anesthesia type and adjunctive analgesics such as esketamine, thereby facilitating tailored analgesic protocols.³⁰¹ Similarly, gradient boosting models in major abdominal surgery integrated demographic, clinical, genetic, and psychosocial variables to predict severe postoperative pain with 83.7% accuracy, enabling preemptive, personalized pain management.³⁰² Ensemble ML approaches have also been applied in spine surgery. Stacking classifiers effectively predicted postoperative axial pain intensity in 484 patients with degenerative cervical myelopathy, achieving an AUC of 0.91, while ensemble models forecasted 1-year functional recovery (Japanese Orthopedic Association scores) in 672 patients, providing clinicians with interpretable, patient-specific insights for optimized pain management and resource allocation.^303,304 Overall, ML and artificial intelligence techniques provide robust tools for objective pain assessment, identification of high-risk patients, and integration of precision analgesic strategies. Across diverse surgical populations, these approaches enhance the ability to predict pain trajectories, tailor opioid and multimodal analgesia, and improve perioperative outcomes.³⁰⁵

Recent studies have developed multimodal machine learning frameworks for objective postoperative pain assessment using biosignals such as ECG, EMG, EDA, and respiration. In a cohort of 25 patients, these models achieved over 80% balanced accuracy, with respiration signals most effective for low pain and EMG for high pain, demonstrating feasibility for real-world clinical monitoring.³⁰⁶ Similarly, automated pain assessment using galvanic skin response (GSR) in 25 non-communicative postoperative adults achieved up to 86% accuracy with random forest and k-nearest-neighbor classifiers, outperforming previous approaches.³⁰⁷ Despite their promise, high costs and technical complexity—including real-time monitoring, AI-driven analytics, pharmacogenomic integration, and wearable sensors—remain significant barriers to widespread adoption, particularly in low-resource healthcare settings.²⁶⁹

Digital and Wearable Innovations in Pain Monitoring and Management

Wearable devices and digital health technologies enable real-time monitoring, objective assessment, and personalized interventions for chronic and postoperative pain.^308–315 Many studies link physiological markers with pain. Traditional models such as Random Forest and multilevel models perform reliably. Advanced models face challenges with data quality and computational demands. Integrating multimodal data and enhancing data security could improve predictive accuracy and clinical utility.³⁰⁸

Integration of wearables with electronic health records (EHRs), especially Epic systems, is increasing. Partnerships between start-ups and health systems have improved data capture and provider workflows. Insurance programs also incentivize wearable use. Remaining challenges include privacy, interoperability, and data overload.³⁰⁹ Pain assessment in children is challenging due to its subjective nature. Validated tools enable accurate postoperative pain evaluation, improving comfort and recovery.³¹⁰ Parents often under-treat pain at home. Factors such as age, development, language, cultural beliefs, and biology influence management. Using multiple assessment tools with technology supports effective pediatric pain care.³¹¹ Technology-based interventions—including apps, virtual reality, and wearables—reduce postoperative pain scores in children, as shown in a meta-analysis of 14 RCTs.³¹²

Digital therapeutics, including virtual reality and mobile applications, improve opioid-based pain management as adjuncts, demonstrating better pain scores in randomized trials. They provide opportunities to enhance patient-centered care and integrate with pharmacotherapy.³¹⁶ Researchers at WashU developed an uncertainty-aware machine learning model using preoperative surveys and clinical data to predict risk, offering clinicians both probability and confidence estimates.⁵⁵ However, precision perioperative medicine applies genetics, pharmacogenomics, and predictive analytics to personalize anesthetic care, optimize drug dosing, anticipate complications, and enhance pain management, thereby improving safety, recovery, and patient-centered outcomes.³¹⁷

Wearables combined with ecological momentary assessment can track activity, physiological signals, and pain in real-world settings. These tools generate reproducible biosignals and clinically meaningful endpoints.³¹³ AI and machine learning enable dynamic, patient-specific pain management. By analyzing large datasets, these systems predict pain trajectories, optimize medications, reduce side effects, and enhance recovery.³¹⁴

Chronic pain often disrupts physical and cognitive function. Conventional therapies are limited and may have side effects. Neuromodulation approaches—including SCS, TENS, NMES, and AI-driven platforms like EcoAI—offer adaptive, personalized treatment. Combined with remote monitoring and closed-loop feedback, these strategies support scalable, precision-based pain management. Future work should focus on validated biomarkers and equitable implementation.³¹⁵

Limitations and Safety Considerations of Systemic Analgesics

Opioids remain indispensable for controlling severe postoperative pain, yet their use is constrained by well-documented adverse effects including nausea, vomiting, constipation, and respiratory depression, with an ongoing risk of misuse even in short-term perioperative settings.³¹⁸ Despite their theoretical utility, gabapentinoids such as gabapentin and pregabalin have demonstrated limited clinical efficacy in postoperative pain, with meta-analyses indicating minimal analgesic benefit and increased risks of dizziness and visual disturbances, challenging their routine use despite potential opioid-sparing properties.^173,319 This highlights the need for careful patient selection and reconsideration of gabapentinoid use in standard postoperative protocols.

Esmolol, an ultra–short-acting selective β-blocker (0.5 mg/kg loading, then 5 μg/kg/min IV), is used for perioperative analgesia, possibly via central G-protein activation. It enhances pain control and hemodynamic stability while reducing opioid and anesthetic requirements, though excessive dosing can cause bradycardia and hypotension.³²⁰ A systematic review and meta-analysis of 19 placebo-controlled trials (1,028 patients) demonstrated that intraoperative esmolol reduced opioid use by 32% intraoperatively and 38.6% postoperatively, improved early postoperative pain scores, and lowered heart rate and mean arterial pressure without inducing clinically significant hypotension or bradycardia, confirming its role as an effective opioid-sparing adjunct in multimodal anesthesia.³²¹

For dexamethasone, major gaps remain regarding its precise analgesic mechanisms, the relative roles of systemic versus perineural effects in nerve block prolongation, optimal dosing, efficacy in preventing persistent postoperative pain, and long-term safety across surgical populations.³²⁰ Rebound pain after single-shot interscalene block affects about one-third of patients. In a factorial RCT of 160 shoulder arthroscopy patients, intravenous dexamethasone reduced both pain escalation and severe rebound pain, whereas esketamine alone had no preventive effect.³²² In a separate RCT of 200 patients, intravenous esketamine did not reduce rebound pain incidence (~25%) but significantly improved pain scores at 8–24 hours and enhanced intraoperative hemodynamic stability without serious adverse events.³²³ These findings underscore the need for further research to clarify dosing strategies, mechanisms, and long-term outcomes of these adjuncts in multimodal analgesia.

Intravenous lidocaine, while effective in specific patient subsets, carries substantial risk and demands strict dosing and monitoring protocols, limiting its broad applicability.⁶ Evidence indicates that combining acetaminophen with NSAIDs yields superior analgesia without amplifying adverse effects, reinforcing the central role of multimodal, non-opioid strategies.³²⁴ Non-opioid analgesics, including acetaminophen, NSAIDs, and coxibs, effectively modulate nociceptive pathways but require caution in populations with comorbidities such as renal impairment.^93,121 Antidepressants, particularly tricyclic antidepressants (TCAs), may provide adjunctive benefits in pain management through modulation of serotonergic and noradrenergic systems, underscoring the interplay between pain and mood regulation.³²⁵

Multimodal analgesia has emerged as the evidence-based standard for postoperative pain management, optimizing efficacy while reducing opioid consumption and associated adverse outcomes.³²⁶ The greatest opioid-sparing effects were observed with NSAIDs combined with dexamethasone or regional anesthesia, while acetaminophen contributed less benefit.¹⁷ The findings reinforce the effectiveness of multimodal analgesia and support prioritizing NSAIDs and dexamethasone within perioperative pain management protocols.¹⁷ Multimodal postoperative analgesia combines pharmacological strategies (opioids, non-opioids, neuraxial and regional techniques, surgical-site infiltration) with non-pharmacological adjuncts such as acupuncture, music therapy, TENS, and hypnosis, which are generally safe but supported by mixed evidence.³²⁷ Although guidelines advocate individualized, preplanned multimodal analgesia, fewer than half of surgical patients achieve adequate pain control, reflecting limited high-quality evidence and suboptimal implementation.²³⁹ In primary total knee arthroplasty, evidence supports a combination of preoperative and intraoperative strategies—including paracetamol, NSAIDs, adductor canal block, local infiltration analgesia, and dexamethasone—while limiting postoperative opioid use. Certain interventions, including gabapentinoids, ketamine, and select nerve blocks, may offer minimal additional benefit and could introduce risk, reflecting the need for individualized, evidence-driven protocols.³²⁸ Importantly, opioid combination therapy has been associated with increased mortality compared to monotherapy, emphasizing the clinical imperative of judicious use.³²⁹

Local anesthetics provide potent, targeted analgesia with fewer systemic effects, and techniques such as epidural and paravertebral blocks reduce chronic postsurgical pain following thoracotomy and breast surgery.^330,331 Complementary and alternative therapies are widely used but are supported by limited or variable evidence, reinforcing their role as adjuncts rather than primary strategies.³³² Non-pharmacologic modalities, including physical therapy, acupuncture, electrical stimulation, cold therapy, and CBT, demonstrate potential in optimizing pain outcomes, particularly when integrated into multimodal frameworks.³³³

The strategic combination of opioids and non-opioids, exploiting distinct mechanisms, provides additive or synergistic analgesic effects and reduces single-agent toxicity(Figure 2).⁶⁹ Safety data from MNK-155 studies indicate substantial TEAEs, though consistent with low-dose opioid/APAP regimens, highlighting the need to balance efficacy and tolerability.³³⁴ Combined oxycodone and flurbiprofen axetil therapy exemplifies effective multimodal postoperative pain control, providing both analgesic and anti-inflammatory effects.³³⁵ Certain patient populations warrant additional scrutiny. SSRIs increase bleeding risk with NSAID co-administration, mandating alternative antidepressants for high-risk individuals.³³⁶ Bariatric surgery alters drug pharmacokinetics, requiring individualized analgesic strategies; NSAIDs are contraindicated after gastric bypass due to ulceration risk, while monitoring remains critical even for sleeve gastrectomy patients.^337–339

Peripheral nerve blocks remain a cornerstone in reducing perioperative opioid requirements, particularly within the first 72 hours; however, rebound hyperalgesia may paradoxically increase opioid consumption, highlighting the complexity of postoperative analgesia.^11,340 Anesthetic co-adjuvants, including clonidine, dexmedetomidine, ketamine, and magnesium sulfate, offer mechanistic benefits such as improved analgesic efficacy and intraoperative hemodynamic stability, yet their clinical value is heterogeneous and procedure-dependent.¹⁶⁵ Opioid-gabapentinoid combinations, while mitigating gastrointestinal side effects, may exacerbate CNS depression and mortality, particularly in cancer patients, underscoring the need for risk-stratified application.³²⁹ Adjunctive postoperative pain management includes physiotherapy and diverse non-pharmacological strategies that are low-cost, low-risk, and easy to implement. Although evidence is insufficient to recommend surgery-specific approaches, commonly used methods include physical modalities (TENS, acupuncture, heat/cold), physical activity, psychological or spiritual techniques (CBT, meditation), and distraction. Patient education and multidisciplinary care further enhance pain control.¹⁰⁴ Optimizing postoperative pain depends on personalized, evidence-based multimodal analgesia integrating pharmacological, regional, and non-pharmacological strategies. Important gaps persist in evaluating optimal combinations and high-risk groups. Effective perioperative pain care requires dedicated pain teams, function-focused assessment, preoperative risk screening, shared decision-making, judicious opioid use, and standardized discharge planning to improve outcomes.²⁵⁴

Post-Discharge Multimodal Analgesia: Opportunities for Optimization

Despite the proliferation of ERAS protocols, most research remains confined to inpatient care, leaving post-discharge multimodal analgesia (MMA) poorly characterized.³⁴¹ This gap contributes to suboptimal pain control, ongoing opioid use, and risk of chronic postsurgical pain(Figure 1). Standardization of analgesic regimens beyond the immediate postoperative period is lacking, and evidence for balancing effective pain relief with minimal opioid exposure remains limited.^341,342 Heterogeneous study designs, variable protocols, and inconsistent outcome reporting further constrain interpretation and generalizability across procedures and institutions.^342,343

Optimal analgesic strategies for high-risk or complex surgeries remain controversial. While neuraxial techniques, including epidurals, reliably reduce pain scores, they do not consistently affect morbidity or length of stay.³⁴⁴ Emerging regional techniques show promise, but few large, procedure-specific RCTs exist to establish best practices. Moreover, patient-centered outcomes—including psychosocial factors, quality of life, and long-term recovery—are rarely evaluated, limiting the understanding of multimodal analgesia’s broader impact.^18,345 Post-discharge pain management is especially inconsistent. Scoping reviews identify gaps in patient education, continuity of care, individualized analgesic planning, and knowledge translation.³⁴⁶ High-quality studies are needed to define procedure-specific multimodal regimens, integrate non-pharmacologic adjuncts such as physical therapy and digital tools, and evaluate the long-term efficacy and safety of MMA strategies.^18,347

Evidence supports certain pharmacologic components—acetaminophen, NSAIDs, and ketamine—as effective opioid-sparing agents with favorable safety profiles (Tables 1–3).³⁴⁸ Conversely, gabapentinoids and α2-agonists pose sedation risks, and evidence for lidocaine, corticosteroids, and other agents remains inconsistent.³⁴⁸ Despite widespread adoption of multimodal strategies, implementation is uneven, and postoperative pain care is often dictated by individual clinician preference rather than standardized, evidence-based protocols.^18,349 Pharmacogenetics and precision medicine offer opportunities to individualize analgesic therapy, identifying high-risk patients and optimizing opioid efficacy while minimizing adverse effects.^78,350–352 Although biologically plausible and supported by observational data, clinical adoption remains limited by knowledge gaps, inconsistent evidence, lack of standardized protocols, and reimbursement barriers.^78,351 Genetic variability clearly affects postoperative pain outcomes, yet actionable guidance has not yet been integrated into routine clinical practice.³⁵³ Despite widespread advocacy of multimodal analgesia, structured quality measures, standardized protocols, and systematic incorporation of non-pharmacologic and digital adjuncts are lacking, limiting reproducibility and optimization of postoperative outcomes. Emerging technologies and holistic approaches show promise, but implementation evidence is sparse, highlighting a critical need for standardized frameworks, validated metrics, and high-quality trials to evaluate integration across settings.^269,276 Collectively, these observations highlight critical priorities for future research: standardized post-discharge MMA protocols, robust procedure-specific RCTs, integration of psychosocial and non-pharmacologic interventions, and precision approaches incorporating pharmacogenetic and AI-driven tools to optimize pain control, minimize opioid exposure, and enhance recovery.

Table 3 Strategic Overview of Multimodal and Non-Opioid Postoperative Pain Management

Limitations of Current Evidence and Future Directions

Despite substantial advances in perioperative pain management, critical gaps remain in the evidence base supporting multimodal analgesia. Most studies focus on inpatient care, with limited high-quality evidence addressing post-discharge pain management, leaving patients at risk for inadequate analgesia, persistent opioid use, and chronic postsurgical pain (Figure 1). Standardized, procedure-specific protocols tailored to diverse surgical populations are scarce, and long-term outcomes—such as functional recovery, quality of life, and chronic pain prevention—are insufficiently studied. Heterogeneity in study design, patient populations, outcome measures, and analgesic components further limits meta-analysis and consensus on optimal strategies. The efficacy of adjunctive agents—including,NSAIDS, gabapentinoids, ketamine, and selected non-pharmacologic interventions—remains inconsistent. Regional and neuraxial analgesic techniques, while effective, are influenced by technical variability, rebound hyperalgesia, and adverse effects. Psychological and physical modalities demonstrate variable benefits, often dependent on patient engagement and implementation fidelity.

Emerging digital and precision technologies, such as machine learning–based risk stratification, biosignal-guided pain assessment, wearable monitoring, and AI-driven decision support, provide opportunities to tailor analgesia across inpatient and post-discharge phases. However, adoption is limited by cost, technical complexity, interoperability challenges, and lack of long-term outcome data. System-level barriers—including inconsistent clinician training, underutilization of validated pain metrics, and absence of standardized quality indicators—further hinder optimal implementation.

Addressing these gaps requires high-quality, multicenter studies that evaluate post-discharge multimodal analgesia, integrate personalized and pharmacogenomic-guided strategies, and assess long-term outcomes. Evidence-informed, procedure-specific frameworks should combine pharmacologic, regional, and non-pharmacologic modalities, incorporate validated metrics, and support seamless transitions from hospital to home care. Embedding these strategies into guidelines and quality improvement initiatives is essential to enhance analgesic efficacy, reduce opioid exposure, and achieve sustainable, patient-centered perioperative pain management.

Conclusion

Achieving durable functional recovery necessitates a fundamental reorientation from opioid-dependent analgesia toward individualized, multimodal perioperative care —one that demonstrably reduces opioid consumption, mitigates adverse effects, and addresses the biopsychosocial complexity of surgical pain across the full continuum of care. Despite compelling inpatient evidence supporting this transition, critical deficiencies persist in post-discharge standardization, long-term functional recovery, and chronic postsurgical pain prevention — domains where current clinical practice remains insufficient relative to patient burden. Pharmacogenomic-guided prescribing, machine learning–based risk stratification, and wearable monitoring platforms represent promising precision-based frontiers, yet their clinical integration remains contingent upon robust validation, interoperability, and the seamless transition of data between surgical and primary care teams. Realizing the full potential of multimodal analgesia demands procedure-specific, evidence-informed protocols embedded within interdisciplinary care frameworks — bridging the persistent discontinuity between effective inpatient analgesia and the largely unstructured postoperative recovery that follows hospital discharge.